Materiały źródłowe

• #1

  https://www.nhs.uk/conditions/mastocytosis/treatment/

  The treatment options for mastocytosis depend on which type you have and how severe your symptoms are. […] Nearly all medicines used to treat mastocytosis are unlicensed. This means the manufacturers haven’t applied for a licence for their medicine to be used to treat mastocytosis. […] Many experts will use an unlicensed medicine if they think it will be effective and the benefits of treatment outweigh any associated risk. […] Mild to moderate cases of cutaneous mastocytosis can be treated with a very strong steroid cream (topical corticosteroids) for a limited length of time. […] Antihistamines can also be used to treat symptoms of cutaneous or indolent mastocytosis, such as itchiness and skin redness. […] Sodium cromoglicate is a mast cell stabiliser, which means it reduces the amount of chemicals released by the mast cells. This helps relieve symptoms such as diarrhoea and stomach pain.

• #2 Mastocytosis: Types, Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/5908-mastocytosis

  Most people can manage mastocytosis symptoms with medication and by avoiding activities and environments that trigger the condition. […] Healthcare providers cant cure mastocytosis, but they can treat its symptoms and the complications the condition causes. […] Treatment varies based on mastocytosis type and your symptoms. In general, providers use medications and other treatments to ease symptoms. […] Medications for mastocytosis may include: Antacids (H2 blockers) for stomach issues, Antihistamines, to relieve itching, flushing and other skin reactions, Bisphosphonates for osteoporosis, Corticosteroids, to reduce inflammation, Monoclonal antibodies, specifically omalizumab (Xolair), Pain medication. […] Providers may use the following treatments: Ultraviolet (UV) light, to make darkened skin lesions less noticeable, Targeted therapy, Epinephrine to treat anaphylaxis, Chemotherapy, should mastocytosis become cancer. This rarely happens, Allogeneic stem cell (bone marrow) transplantation to treat advanced or aggressive mastocytosis. Very few people with mastocytosis may benefit from this treatment.

• #3 Treatment – The Australasian Mastocytosis Society

  https://mastocytosis.org.au/mast-cells-explained/treatment/

  There is no cure for mastocytosis, several treatments can be used to relieve symptoms. […] An important part of treating mastocytosis is controlling a person’s symptoms. One important way to do this is to avoid anything that may cause mast cells to release mediators like histamine, one of hundreds of mediators. […] Doctors may recommend the following treatments to help manage symptoms of mastocytosis. […] Antihistamines (H1/H2): Antihistamines can help by alleviating symptoms triggered by the release of histamine, such as itching, welting, flushing, gastrointestinal discomfort, as well as respiratory, sinus and airway symptoms. […] Epinephrine: People with mastocytosis often carry a syringe of epinephrine, a hormone made by the adrenal glands, in case they need to treat a severe allergic reaction.

• #4 Systemic mastocytosis – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/systemic-mastocytosis/diagnosis-treatment/drc-20450478

  Treatment may vary, depending on the type of systemic mastocytosis and the body organs affected. Treatment generally includes controlling symptoms, treating the disease and regular monitoring. […] Identifying and avoiding factors that may trigger your mast cells, such as certain foods, medications or insect stings, can help keep your systemic mastocytosis symptoms under control. […] Your doctor may recommend medications to: Treat symptoms, for example, with antihistamines; Reduce stomach acid and discomfort in your digestive system; Counteract the effects of the substances released by your mast cells, for example with corticosteroids; Inhibit the KIT gene to reduce the production of mast cells. […] If you have aggressive systemic mastocytosis, systemic mastocytosis associated with another blood disorder or mast cell leukemia, you may be treated with chemotherapy medications to reduce the number of mast cells.

• #5 Treatment of Indolent and Advanced Systemic Mastocytosis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9084172/

  Management of Indolent SM (ISM) and Smoldering SM (SSM) is focused on the prevention and treatment of anaphylactic reactions and symptom control. In case of severe symptoms refractory to anti-mediator therapy or bone disease unresponsive to bisphosphonates, disease-modifying treatments with cytoreductive agents may be attempted. […] The first approach is to identify symptom triggers and suggest avoidance strategies of triggers, such as physical stimuli (heat, change of temperature, pressure, cold, rubbing), exercise, sleep deprivation, emotions, drugs (opiates, contrast media, succinylcholine, nonsteroidal anti-inflammatory drugs, agents with tetrahydroisoquinoline such as quinolones, atracurium, and rocuronium), alcohol, food, and Hymenoptera stings. […] When H1-antihistamines do not adequately control skin symptoms, leukotriene antagonists (montelukast 10 mg, zafirlukast 20 mg bid) may be added.

• #6 What are treatments for Systemic Mastocytosis? – HealthTree for Systemic Mastocytosis

  https://healthtree.org/mastocytosis/community/what-are-treatments-for-systemic-mastocytosis

  Systemic mastocytosis is a rare disorder characterized by an excessive accumulation of mast cells (a type of white blood cell) in various body organs, including the skin, bone marrow, liver, spleen, and gastrointestinal tract. This can lead to a variety of symptoms, such as skin lesions, abdominal pain, diarrhea, and anaphylaxis. […] The treatment of systemic mastocytosis typically aims to control symptoms and prevent complications. The choice of treatment depends on the severity of the disease, the organs involved, and the patient’s overall health status. […] The main treatment options for systemic mastocytosis include medications to control symptoms, chemotherapy, and stem cell transplantation. […] The first line of treatment for systemic mastocytosis often involves medications to control symptoms.

• #7

  https://www.nhs.uk/conditions/mastocytosis/treatment/

  Cladribine is an alternative medicine to midostaurin. […] Avapritinib is a medicine that can be used to treat advanced systemic mastocytosis in adults. […] Systemic mastocytosis with associated blood (haematological) disease will be treated in the same way as aggressive systemic mastocytosis, with a number of additional treatments for the related haematological condition. […] Because of your increased risk of anaphylaxis, you may be given an adrenaline auto-injector to use in an emergency.

• #8 Mastocytosis: Types, Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/5908-mastocytosis

  Most people can manage mastocytosis symptoms with medication and by avoiding activities and environments that trigger the condition. […] Healthcare providers cant cure mastocytosis, but they can treat its symptoms and the complications the condition causes. […] Treatment varies based on mastocytosis type and your symptoms. In general, providers use medications and other treatments to ease symptoms. […] Medications for mastocytosis may include: Antacids (H2 blockers) for stomach issues, Antihistamines, to relieve itching, flushing and other skin reactions, Bisphosphonates for osteoporosis, Corticosteroids, to reduce inflammation, Monoclonal antibodies, specifically omalizumab (Xolair), Pain medication. […] Providers may use the following treatments: Ultraviolet (UV) light, to make darkened skin lesions less noticeable, Targeted therapy, Epinephrine to treat anaphylaxis, Chemotherapy, should mastocytosis become cancer. This rarely happens, Allogeneic stem cell (bone marrow) transplantation to treat advanced or aggressive mastocytosis. Very few people with mastocytosis may benefit from this treatment.

• #9 Treatment of Indolent and Advanced Systemic Mastocytosis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9084172/

  Oral psoralen combined with ultraviolet therapy is reserved for patients with cutaneous mastocytosis (urticarial pigmentosa) in case of severe/resistant skin symptoms. […] H2-antagonists (ranitidine 150 mg bid, famotidine 10 mg bid, cimetidine 400 mg bid) are the drug of choice in case of gastrointestinal symptoms. Proton pump inhibitors (omeprazole 20 mg, pantoprazole 40 mg, rabeprazole 20 mg) are second line drugs in case H2-antihistamines are not effective. Sodium cromolyn at a dose of 8001200 mg daily divided into four doses is a third-line treatment. Oral corticosteroids (prednisone 0.51 mg/kg/day or equivalent) are the fourth-line drug for gastrointestinal symptoms. […] The prevalence of anaphylaxis in adults with SM ranges from 22 to 49%, about 100 times higher than the general population. Anaphylaxis may be provoked by a concomitant IgE-mediated allergy (especially to Hymenoptera venoms) or may also be spontaneous. Thus, all patients should be prescribed self-injectable epinephrine and should be trained to treat attacks.

• #10 Cutaneous mastocytosis treatment: strategies, limitations and perspectives

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6320483/

  To summarize, pure CM in children is mostly a benign and transient disease. Therefore, the main aim of treatment is to control mediator-related symptoms with antihistamines and short-term topical corticosteroids therapy. In adults, the disease limited to the skin is a rarity and treated mainly as a cosmetic problem. In the majority of adults, skin involvement is associated with SM. Thus, drug administration, prevention and follow-up should be individualized depending on disease manifestation.

• #11 Cutaneous mastocytosis treatment: strategies, limitations and perspectives

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6320483/

  Mastocytosis is a rare myeloproliferative disease, characterized by excessive proliferation and accumulation of mast cells in the tissues. The first-line treatment in CM is antimediator therapy (mainly H1 and H2 antihistamines) and short-term topical corticosteroids. Phototherapy is the second-line therapy which may be considered when antihistamines do not produce the expected improvement. New therapeutic options include omalizumab and KIT-targeting agents. In all adults with mastocytosis and in pediatric patients with severe CM, a persistently elevated serum tryptase level and anaphylaxis in medical history, equipping with epinephrine autoinjector for use in case of anaphylaxis is recommended. […] The primary goal of CM treatment is the control of mast cell mediator-related symptoms. The antagonists of the histamine receptor are the basis of therapy. Skin symptoms such as pruritus, flushing and the sensation of burning of the skin may be controlled by first-generation and second-generation H1 antihistamines. If symptoms persist although maximum doses of H1 antihistamines are used, it is reasonable to add H2 antihistamines and leukotriene antagonist, such as montelukast.

• #12

  https://www.nhs.uk/conditions/mastocytosis/treatment/

  The treatment options for mastocytosis depend on which type you have and how severe your symptoms are. […] Nearly all medicines used to treat mastocytosis are unlicensed. This means the manufacturers haven’t applied for a licence for their medicine to be used to treat mastocytosis. […] Many experts will use an unlicensed medicine if they think it will be effective and the benefits of treatment outweigh any associated risk. […] Mild to moderate cases of cutaneous mastocytosis can be treated with a very strong steroid cream (topical corticosteroids) for a limited length of time. […] Antihistamines can also be used to treat symptoms of cutaneous or indolent mastocytosis, such as itchiness and skin redness. […] Sodium cromoglicate is a mast cell stabiliser, which means it reduces the amount of chemicals released by the mast cells. This helps relieve symptoms such as diarrhoea and stomach pain.

• #13 Mastocytosis — DermNet

  https://dermnetnz.org/topics/mastocytosis

  Many forms of cutaneous mastocytosis without symptoms require no treatment. […] Avoidance of triggers for histamine release/ mast cell degranulation is important in patients with symptomatic mastocytosis. […] An adrenaline (epinephrine) autoinjector (eg, EpiPen) is recommended in patients with previous anaphylaxis, high tryptase, or significant cutaneous disease. […] Specific treatments for patients with cutaneous mastocytosis may include: Non-sedating H1 antihistamines, H2 antihistamines (eg, cimetidine, ranitidine) or proton pump inhibitors (eg, omeprazole, lansoprazole, or pantoprazole) for gastrointestinal symptoms such as diarrhoea and reflux, Topical steroids, Montelukast, Phototherapy eg, narrowband UVB phototherapy or PUVA (photochemotherapy). […] Systemic mastocytosis treatments include: Imatinib and other tyrosine inhibitors (midostaurin), Avapritinib targets the KIT gene and has been FDA (in the US) and NICE approved (in the UK) for treating advanced systemic and indolent disease and has been shown to reduce uncontrolled systemic symptoms of mastocytosis and serum tryptase levels, Cytoreductive treatment in systemic mastocytosis can result in disappearance of skin lesions in these patients, Rapidly progressive systemic mastocytosis, mast cell leukaemia, and mast cell sarcoma may be treated with chemotherapy and bone marrow stem cell transplantation.

• #14

  https://www.nhs.uk/conditions/mastocytosis/treatment/

  The treatment options for mastocytosis depend on which type you have and how severe your symptoms are. […] Nearly all medicines used to treat mastocytosis are unlicensed. This means the manufacturers haven’t applied for a licence for their medicine to be used to treat mastocytosis. […] Many experts will use an unlicensed medicine if they think it will be effective and the benefits of treatment outweigh any associated risk. […] Mild to moderate cases of cutaneous mastocytosis can be treated with a very strong steroid cream (topical corticosteroids) for a limited length of time. […] Antihistamines can also be used to treat symptoms of cutaneous or indolent mastocytosis, such as itchiness and skin redness. […] Sodium cromoglicate is a mast cell stabiliser, which means it reduces the amount of chemicals released by the mast cells. This helps relieve symptoms such as diarrhoea and stomach pain.

• #15

  https://www.nhs.uk/conditions/mastocytosis/

  There’s no cure for mastocytosis, so the aim of treatment is to try to relieve the symptoms. […] Treatment options will depend on the type of mastocytosis and the severity of the symptoms. […] Mild to moderate cases of cutaneous mastocytosis can be treated with steroid cream (topical corticosteroids) for a short time. […] Steroid cream reduces the number of mast cells that can release histamine and trigger swelling (inflammation) in the skin. […] Antihistamines can also be used to treat the symptoms of cutaneous or indolent mastocytosis, such as red skin and itchiness. […] Antihistamines are a type of medicine that block the effects of histamine and are often used to treat allergic conditions.

• #16 Cutaneous and Systemic Manifestations of Mastocytosis | AAFP

  https://www.aafp.org/pubs/afp/issues/1999/0601/p3047.html

  Aspirin has been used to treat the flushing that is associated with elevated prostaglandin levels during attacks. Caution is required, however, because of the potential for aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) to cause degranulation. Treatment with aspirin is reserved for use in patients with vascular collapse that is not prevented by H1 and H2 blocker prophylaxis. […] PUVA therapy may provide cosmetic skin changes and temporary relief from symptoms. High-potency topical or intralesional injection of corticosteroids affords only transient improvement. Topical or intralesional corticosteroid therapy is, however, useful in the treatment of solitary mastocytoma. Systemic steroids may be necessary to control the severe skin disease, malabsorption or ascites of systemic mastocytosis.

• #17 Cutaneous mastocytosis treatment: strategies, limitations and perspectives

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6320483/

  Phototherapy or photochemotherapy may be considered as therapeutic options because they result in partial remission of skin lesions and pruritus reduction. Therefore, it is recommended to use NB-UVA, UVA1 or PUVA therapy as second-line therapy, when antihistamines do not result in reduction of mast cell mediator-related symptoms. […] In recent years, omalizumab, a monoclonal antibody which selectively binds human IgE, has been shown to be a favorable therapeutic option in mastocytosis associated with recurrent anaphylaxis. Imatinib mesylate, an oral tyrosine kinase inhibitor, is approved by the US Food and Drug Administration for treatment of aggressive SM without the D816V KIT mutation or with an unknown mutation status. […] The cytoreductive therapy in patients with SM usually results in partial or complete remission of cutaneous symptoms. The raft modulator such as miltefosine, seems to be a promising option in topical treatment of CM.

• #18

  https://www.nhs.uk/conditions/mastocytosis/treatment/

  More severe symptoms of cutaneous mastocytosis, such as severe itchy skin, may require a type of treatment called psoralen plus ultraviolet A (PUVA). […] If symptoms such as itchiness are particularly severe, corticosteroid tablets (oral corticosteroids) may be prescribed on a short-term basis. […] If you have weakened bones (osteoporosis) resulting from abnormal mast cell activity in your bones, you’ll be given a medicine called bisphosphonates. […] Originally designed to treat cancer, interferon alpha has proved effective in treating some cases of aggressive mastocytosis. […] Imatinib is an alternative medicine to interferon alpha. […] Nilotinib or dasatinib may be recommended if you do not respond to treatment with imatinib. […] Midostaurin is a licensed medicine that can be used to treat advanced systemic mastocytosis.

• #19 Mastocytosis treatment – USZ

  https://www.usz.ch/en/department/dermatology/service/mastocytosis-treatment/

  Systemic mastocytosis is a rare disease of the mast cells. […] The treatment of systemic mastocytosis is predominantly symptomatic. The focus is on avoiding foods, medications and situations that experience has shown to lead to symptoms caused by histamine release in individual cases. Older antihistamines are usually used as medication; their sedative effect is deliberately used to reduce the release of histamine. Low doses of benzodiazepines are often used for the same reason. As with other malignant diseases, aggressive forms are often treated experimentally with ciclosporin, corticosteroids and interferon -2b without any evidence of their efficacy. Drugs that can reduce mast cells with high efficiency are now also available. However, these drugs (imatinib, mastinib), which are classified as chemotherapy, are only used for very aggressive forms due to their pronounced side effects and high costs. […] Another therapeutic approach is PUVA, a treatment with psoralen, a photosensitizing substance, and subsequent exposure of the skin to UVA radiation.

• #20 Systemic Mastocytosis Treatment & Management: Medical Care, Surgical Care, Consultations

  https://emedicine.medscape.com/article/203948-treatment

  In patients with anaphylaxis that is recurrent or refractory to conventional therapies, omalizumab (anti-immunoglobulin E [IgE]), a humanized monoclonal antibody that inhibits the binding of IgE to mast cells, reduced the frequency of anaphylaxis in some patients with systemic mastocytosis. […] Corticosteroids have been used to control malabsorption, ascites, abdominal pain refractory to cromolyn, bone pain, and diffuse cutaneous disease refractory to topical therapy, and to prevent anaphylaxis. […] Medical therapy for systemic mastocytosis is generally considered as initial treatment for patients with advanced systemic mastocytosis (aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, mast cell leukemia), as bridging treatment to undergo allogenic hematopoietic cell transplantation, or in selected patients with indolent systemic mastocytosis or smoldering systemic mastocytosis who suffer recurrent anaphylaxis despite treatment with all other options.

• #21 Systemic Mastocytosis Treatment & Management: Medical Care, Surgical Care, Consultations

  https://emedicine.medscape.com/article/203948-treatment

  Therapy for systemic mastocytosis (systemic mast cell disease) is primarily symptomatic; no therapy is curative. Treatment modalities include the management of (1) anaphylaxis and related symptoms, (2) pruritus and flushing, and (3) intestinal malabsorption. The principles of treatment include control of symptoms with measures to decrease mast cell activation. […] Epinephrine is used in acute anaphylaxis. H1 and H2 receptor blockers are used to control anaphylactic symptoms. Antihistamines (H1 and H2 receptor blockers) are part of initial pharmacologic treatment in systemic mastocytosis. […] Cromolyn sodium has demonstrated multiple benefits in systemic mastocytosis. It has proved useful for relieving abdominal pain and diarrhea; pruritus, whealing, and flushing; and impaired cognition.

• #22

  https://www.nhs.uk/conditions/mastocytosis/treatment/

  The treatment options for mastocytosis depend on which type you have and how severe your symptoms are. […] Nearly all medicines used to treat mastocytosis are unlicensed. This means the manufacturers haven’t applied for a licence for their medicine to be used to treat mastocytosis. […] Many experts will use an unlicensed medicine if they think it will be effective and the benefits of treatment outweigh any associated risk. […] Mild to moderate cases of cutaneous mastocytosis can be treated with a very strong steroid cream (topical corticosteroids) for a limited length of time. […] Antihistamines can also be used to treat symptoms of cutaneous or indolent mastocytosis, such as itchiness and skin redness. […] Sodium cromoglicate is a mast cell stabiliser, which means it reduces the amount of chemicals released by the mast cells. This helps relieve symptoms such as diarrhoea and stomach pain.

• #23 Systemic Mastocytosis Treatment & Management: Medical Care, Surgical Care, Consultations

  https://emedicine.medscape.com/article/203948-treatment

  Therapy for systemic mastocytosis (systemic mast cell disease) is primarily symptomatic; no therapy is curative. Treatment modalities include the management of (1) anaphylaxis and related symptoms, (2) pruritus and flushing, and (3) intestinal malabsorption. The principles of treatment include control of symptoms with measures to decrease mast cell activation. […] Epinephrine is used in acute anaphylaxis. H1 and H2 receptor blockers are used to control anaphylactic symptoms. Antihistamines (H1 and H2 receptor blockers) are part of initial pharmacologic treatment in systemic mastocytosis. […] Cromolyn sodium has demonstrated multiple benefits in systemic mastocytosis. It has proved useful for relieving abdominal pain and diarrhea; pruritus, whealing, and flushing; and impaired cognition.

• #24 Treatment of Indolent and Advanced Systemic Mastocytosis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9084172/

  Management of Indolent SM (ISM) and Smoldering SM (SSM) is focused on the prevention and treatment of anaphylactic reactions and symptom control. In case of severe symptoms refractory to anti-mediator therapy or bone disease unresponsive to bisphosphonates, disease-modifying treatments with cytoreductive agents may be attempted. […] The first approach is to identify symptom triggers and suggest avoidance strategies of triggers, such as physical stimuli (heat, change of temperature, pressure, cold, rubbing), exercise, sleep deprivation, emotions, drugs (opiates, contrast media, succinylcholine, nonsteroidal anti-inflammatory drugs, agents with tetrahydroisoquinoline such as quinolones, atracurium, and rocuronium), alcohol, food, and Hymenoptera stings. […] When H1-antihistamines do not adequately control skin symptoms, leukotriene antagonists (montelukast 10 mg, zafirlukast 20 mg bid) may be added.

• #25 Systemic Mastocytosis Treatment & Management: Medical Care, Surgical Care, Consultations

  https://emedicine.medscape.com/article/203948-treatment

  In patients with anaphylaxis that is recurrent or refractory to conventional therapies, omalizumab (anti-immunoglobulin E [IgE]), a humanized monoclonal antibody that inhibits the binding of IgE to mast cells, reduced the frequency of anaphylaxis in some patients with systemic mastocytosis. […] Corticosteroids have been used to control malabsorption, ascites, abdominal pain refractory to cromolyn, bone pain, and diffuse cutaneous disease refractory to topical therapy, and to prevent anaphylaxis. […] Medical therapy for systemic mastocytosis is generally considered as initial treatment for patients with advanced systemic mastocytosis (aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, mast cell leukemia), as bridging treatment to undergo allogenic hematopoietic cell transplantation, or in selected patients with indolent systemic mastocytosis or smoldering systemic mastocytosis who suffer recurrent anaphylaxis despite treatment with all other options.

• #26 Mastocytosis (Mast Cell Disorder): Symptoms and Treatment

  https://patient.info/doctor/mastocytosis-and-mast-cell-disorders

  Mastocytosis treatment and management is concerned mainly with symptom control, as there is currently no cure. Systemic mastocytosis is usually managed by haematologists. […] Acute anaphylaxis is treated with intramuscular adrenaline (epinephrine), antihistamines (H1 and H2 receptor blockers), fluids and pressor agents. […] For pruritus, weals and flushing – H1 and H2 receptor antagonists such as chlorphenamine, ketotifen and cimetidine. […] Mast cell stabilisers – sodium cromoglicate, nedocromil and ketotifen. […] Systemic corticosteroids may be helpful for malabsorption, ascites and bone pain, to prevent anaphylaxis and for severe skin disease. […] Aggressive systemic forms of mastocytosis may be treated with interferon alfa, pegylated interferon alpha, corticosteroids, or cladribine.

• #27

  https://www.nhs.uk/conditions/mastocytosis/treatment/

  More severe symptoms of cutaneous mastocytosis, such as severe itchy skin, may require a type of treatment called psoralen plus ultraviolet A (PUVA). […] If symptoms such as itchiness are particularly severe, corticosteroid tablets (oral corticosteroids) may be prescribed on a short-term basis. […] If you have weakened bones (osteoporosis) resulting from abnormal mast cell activity in your bones, you’ll be given a medicine called bisphosphonates. […] Originally designed to treat cancer, interferon alpha has proved effective in treating some cases of aggressive mastocytosis. […] Imatinib is an alternative medicine to interferon alpha. […] Nilotinib or dasatinib may be recommended if you do not respond to treatment with imatinib. […] Midostaurin is a licensed medicine that can be used to treat advanced systemic mastocytosis.

• #28 What are treatments for Systemic Mastocytosis? – HealthTree for Systemic Mastocytosis

  https://healthtree.org/mastocytosis/community/what-are-treatments-for-systemic-mastocytosis

  Steroids such as prednisone reduce inflammation and have been used to control gastrointestinal issues like malabsorption, fluid build-up in the abdomen, stomach pain, bone pain, and skin disease that doesn’t respond to topical treatment. Steroids can also be used to prevent anaphylaxis. […] Proton pump inhibitors, such as omeprazole, help with stomach pain and other gastrointestinal symptoms. […] Calcium and Vitamin D prevent bone weakness (osteoporosis) and fractures. […] Chemotherapy can reduce the number of mast cells in the body, helping to control symptoms and prevent complications. These drugs work by interfering with the growth of mast cells, thereby reducing their numbers. One chemotherapy drug commonly used is Cladribine (Leustatin). […] For patients with life-threatening systemic mastocytosis, allogeneic stem cell transplantation may be considered. This involves replacing the patient’s diseased bone marrow (which produces mast cells) with healthy bone marrow from a donor. This can potentially cure the disease, but it carries significant risks, including infection, graft-versus-host disease, and even death. Therefore, it is usually reserved for the most severe cases.

• #29 Systemic Mastocytosis Treatment & Management: Medical Care, Surgical Care, Consultations

  https://emedicine.medscape.com/article/203948-treatment

  In patients with anaphylaxis that is recurrent or refractory to conventional therapies, omalizumab (anti-immunoglobulin E [IgE]), a humanized monoclonal antibody that inhibits the binding of IgE to mast cells, reduced the frequency of anaphylaxis in some patients with systemic mastocytosis. […] Corticosteroids have been used to control malabsorption, ascites, abdominal pain refractory to cromolyn, bone pain, and diffuse cutaneous disease refractory to topical therapy, and to prevent anaphylaxis. […] Medical therapy for systemic mastocytosis is generally considered as initial treatment for patients with advanced systemic mastocytosis (aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, mast cell leukemia), as bridging treatment to undergo allogenic hematopoietic cell transplantation, or in selected patients with indolent systemic mastocytosis or smoldering systemic mastocytosis who suffer recurrent anaphylaxis despite treatment with all other options.

• #30 Successful treatment with Omalizumab of a child affected by Systemic Mastocytosis: clinical and biological implications | Italian Journal of Pediatrics | Full Text

  https://ijponline.biomedcentral.com/articles/10.1186/s13052-022-01402-7

  A child with Systemic Mastocytosis and severe symptoms, refractory to symptomatic and steroidal therapy, has been successfully treated with Omalizumab, an anti-IgE monoclonal antibody usually employed in allergic patients with severe asthma and orticaria. […] In our experience, Omalizumab is an effective treatment for children affected by Systemic Mastocytosis not responding to conventional medical treatments. The main strengths of this therapy are its rapid and extraordinary efficacy to control the severe mast cells mediator-related symptoms, the lack of side effects and its steroid-sparing effect. […] Omalizumab has been well tolerated, without side effects, except for minimal local swelling. […] Twenty months later, Omalizumab therapy is still ongoing. […] Omalizumab is a recombinant humanized murine monoclonal IgG1 antibody, that reversibly binds the free serum IgE at the same site that IgE would bind to its high-affinity receptor (FcRI) on the surface of mast cells and basophils.

• #31 Update on Mastocytosis (Part 2): Categories, Prognosis, and Treatment | Actas Dermo-Sifiliográficas

  https://www.actasdermo.org/en-update-on-mastocytosis-part-2–articulo-S157821901500311X

  Treatment should be individualized according to the type, severity, and frequency of manifestations. […] In addition to general measures, all patients should be administered treatment aimed at controlling symptoms due to mast cell mediator release in accordance with the type and severity of symptoms they typically experience. […] Anti-immunoglobulin E therapy with omalizumab has been used successfully in mastocytosis and is reserved for patients with severe symptoms secondary to mediator release that are refractory to treatment with conventional antimediator therapy. […] In advanced forms of the disease with a high mast cell burden, cytoreductive therapy with hydroxyurea, interferon alfa 2b, or cladribine (2-CdA) is recommended. […] Tyrosine kinase inhibitors may be a promising alternative for the treatment of systemic mastocytosis.

• #32 Treatment of Indolent and Advanced Systemic Mastocytosis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9084172/

  Management of Indolent and Smoldering SM is focused on preventing anaphylactic reactions and identifying and avoiding symptom triggers. Skin and gastrointestinal symptoms are managed with H1- and H2-antihistamines. When skin symptoms are not adequately controlled, leukotriene antagonists and oral psoralen combined with ultraviolet therapy may be added. Proton pump inhibitors, sodium cromolyn, and oral corticosteroids may be added for gastrointestinal symptoms. Patients should be prescribed self-injectable epinephrine and trained to treat recurrent cardiovascular symptoms or anaphylaxis. Depression and cognitive impairment require a psychiatric evaluation for tailored treatment. Bone involvement is managed with bisphosphonates and eventually interferon. Omalizumab is effective on all vasomotor symptoms, including anaphylaxis, but not on respiratory, musculoskeletal, and neuropsychiatric symptoms. A cytoreductive treatment is not recommended unless anti-mediator therapy has failed. Venom immunotherapy is mandatory for patients with Hymenoptera venom allergy. There is no curative option for patients with advanced SM. The available therapeutic options include tyrosine-kinase inhibitors and cladribine, with variable duration and extent of response.

• #33 What are treatments for Systemic Mastocytosis? – HealthTree for Systemic Mastocytosis

  https://healthtree.org/mastocytosis/community/what-are-treatments-for-systemic-mastocytosis

  Antihistamines, such as cetirizine and loratadine, help manage skin symptoms like flushing and itching, as well as gastrointestinal issues like stomach pain, heartburn, cramping, and diarrhea. […] Mast cell stabilizers, such as cromolyn sodium, prevent mast cells from releasing harmful substances, helping with allergy-like symptoms like rash, itching, and eye inflammation. […] Antileukotriene drugs may be an option in patients with flushing, itching, or cramping who do not respond to antihistamines. […] Injectable epinephrine is sometimes needed if patients experience a full-body allergic reaction called anaphylaxis. […] Monoclonal antibodies such as omalizumab (anti-IgE) can reduce the frequency of anaphylaxis. […] Tyrosine kinase inhibitors (TKI inhibitors) such as midostaurin (Rydapt), avapritinib (Ayvakit), imatinib mesylate (Gleevec) are used like a directed therapy because they act by blocking enzymes that control the mast cell functions and growth.

• #34 Systemic Mastocytosis Treatment & Management: Medical Care, Surgical Care, Consultations

  https://emedicine.medscape.com/article/203948-treatment

  Tyrosine kinase inhibitors (TKIs) have shown benefit in treatment of systemic mastocytosis. In 2017, the FDA approved midostaurin (Rydapt), which inhibits multiple receptor tyrosine kinases, for aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell leukemia (MCL), collectively referred to as advanced systemic mastocytosis. […] In 2021, the FDA approved avapritinib (Ayvakit) for treatment of adult patients with advanced systemic mastocytosis (AdvSM). […] The TKI imatinib mesylate (Gleevec) may be useful in those types of systemic mastocytosis that do not have mutations of the codon 816 on the c-kit gene and carry the wild-type kit. […] Allogeneic hematopoietic cell transplantation is the only treatment that has the proven ability to cure advanced systemic mastocytosis but is considered experimental and is being pursued in clinical trials at the US National Institutes of Health (NIH).

• #35 Mastocytosis (Mast Cell Disorder): Symptoms and Treatment

  https://patient.info/doctor/mastocytosis-and-mast-cell-disorders

  The National Institute for Health and Care Excellence (NICE) recommends midostaurin monotherapy as an option for treating aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm, or mast cell leukaemia in adults. […] Bone marrow transplantation may be considered in some extreme cases. […] For patients with mast cell sarcoma, surgical excision with consecutive radiation and/or high-dose chemotherapy has been used.

• #36 Systemic Mastocytosis Treatment & Management: Medical Care, Surgical Care, Consultations

  https://emedicine.medscape.com/article/203948-treatment

  Tyrosine kinase inhibitors (TKIs) have shown benefit in treatment of systemic mastocytosis. In 2017, the FDA approved midostaurin (Rydapt), which inhibits multiple receptor tyrosine kinases, for aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell leukemia (MCL), collectively referred to as advanced systemic mastocytosis. […] In 2021, the FDA approved avapritinib (Ayvakit) for treatment of adult patients with advanced systemic mastocytosis (AdvSM). […] The TKI imatinib mesylate (Gleevec) may be useful in those types of systemic mastocytosis that do not have mutations of the codon 816 on the c-kit gene and carry the wild-type kit. […] Allogeneic hematopoietic cell transplantation is the only treatment that has the proven ability to cure advanced systemic mastocytosis but is considered experimental and is being pursued in clinical trials at the US National Institutes of Health (NIH).

• #37 Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

  https://www.onclive.com/view/advanced-systemic-mastocytosis-expert-insight-into-epidemiology-diagnosis-and-treatment

  Treatment options for advanced SM are limited, which likely reflects the diagnostic challenges and lack of clinical biomarkers. Historically, clinicians have relied on chemotherapy and stem cell transplants to treat aggressive SM, but targeted options are available, and others are in development. […] Midostaurin is an oral multikinase inhibitor that inhibits D816V-mutated KIT. It is FDA approved for the treatment of patients with advanced SM. […] For patients with aggressive SM who do not have the D816V c-KIT mutation or whose mutational status is unknown, imatinib is an FDA-approved treatment option. […] In June 2020, the FDA approved avapritinib for the treatment of adult patients with advanced SM, including those with aggressive SM, SM with an associated hematologic neoplasm, and MC leukemia. Avapritinib is a potent and selective KIT D816V inhibitor.

• #38 Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

  https://www.onclive.com/view/advanced-systemic-mastocytosis-expert-insight-into-epidemiology-diagnosis-and-treatment

  Avapritinib therapy led to a notable reduction in BM MCs, with 88% of patients achieving a greater than 50% reduction and 60% of patients achieving elimination of marrow MC aggregates. Additionally, 93% of patients achieved a greater than 50% reduction in serum tryptase level, 60% of patients achieved a 50% or greater reduction in variant allele frequency, and 66% of patients achieved a greater than 35% reduction in spleen volume. […] According to DeAngelo, these findings may have particular meaning for patients. One of the important features of our job is to make patients feel better. And so here, you can see this significant rapid reduction in their total symptom score. All of these symptoms improved in patients who had them, so I think that that is just an important observation. […] Lugar agreed and expressed hope that these results would bear out in continued evaluation of avapritinib. I hope that the same symptom score for indolent [cases] as well carries over in further trials, because thats the most difficult thingmanaging the chronic symptoms, she said. Even if we know these patients are stable, they dont have a disease thats going to be progressive, the majority of them, but managing the day-to-day symptoms is such a [benefit toward managing] the burden of disease. […] This is a drug [that] is hitting the target to a greater depth, said Bose. This is a more potent and more selective inhibitor of mutant KIT, so I hope we are sparing wild-type KIT a little bit more.

• #39 FDA Approves New Treatment for Rare Blood Disorder | Leukemia and Lymphoma Society

  https://www.lls.org/news/fda-approves-new-treatment-rare-blood-disorder

  The U.S. Food and Drug Administration (FDA) recently approved avapritinib (Ayvakit) to treat adults with indolent systemic mastocytosis. […] The development of avapritinib, a treatment that targets the KIT gene, can be traced back to the tireless work and investments LLS made in imatinib, a related and groundbreaking targeted treatment known as Gleevec, said Lee Greenberger, PhD, Chief Scientific Officer of LLS. […] The FDA based its decision to approve this new use of avapritinib, which was previously approved for an advanced form of the disease, on study results that showed this treatment plus supportive care is effective in improving disease symptoms.

• #40 Systemic Mastocytosis Treatment & Management: Medical Care, Surgical Care, Consultations

  https://emedicine.medscape.com/article/203948-treatment

  Tyrosine kinase inhibitors (TKIs) have shown benefit in treatment of systemic mastocytosis. In 2017, the FDA approved midostaurin (Rydapt), which inhibits multiple receptor tyrosine kinases, for aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell leukemia (MCL), collectively referred to as advanced systemic mastocytosis. […] In 2021, the FDA approved avapritinib (Ayvakit) for treatment of adult patients with advanced systemic mastocytosis (AdvSM). […] The TKI imatinib mesylate (Gleevec) may be useful in those types of systemic mastocytosis that do not have mutations of the codon 816 on the c-kit gene and carry the wild-type kit. […] Allogeneic hematopoietic cell transplantation is the only treatment that has the proven ability to cure advanced systemic mastocytosis but is considered experimental and is being pursued in clinical trials at the US National Institutes of Health (NIH).

• #41 Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

  https://www.onclive.com/view/advanced-systemic-mastocytosis-expert-insight-into-epidemiology-diagnosis-and-treatment

  Treatment options for advanced SM are limited, which likely reflects the diagnostic challenges and lack of clinical biomarkers. Historically, clinicians have relied on chemotherapy and stem cell transplants to treat aggressive SM, but targeted options are available, and others are in development. […] Midostaurin is an oral multikinase inhibitor that inhibits D816V-mutated KIT. It is FDA approved for the treatment of patients with advanced SM. […] For patients with aggressive SM who do not have the D816V c-KIT mutation or whose mutational status is unknown, imatinib is an FDA-approved treatment option. […] In June 2020, the FDA approved avapritinib for the treatment of adult patients with advanced SM, including those with aggressive SM, SM with an associated hematologic neoplasm, and MC leukemia. Avapritinib is a potent and selective KIT D816V inhibitor.

• #42 Treatments – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/treatments/

  Therapies exist for smoldering systemic mastocytosis (SSM) and advanced systemic mastocytosis, and promising new treatments are being developed. Prominent among these newer treatments are tyrosine kinase inhibitors (TKIs) targeting the KIT kinase (e.g., midostaurin). Imatinib is approved therapy for adult aggressive systemic mastocytosis (ASM) patients lacking the KIT D816V mutation or if mutation status is unknown. Additional standard therapies for advanced variants are interferon, the chemotherapeutic agent cladribine, and tyrosine kinase inhibitors such as midostaurin. These chemotherapeutic agents are used in combination with antimediator therapy to control symptoms and reduce the overall mast cell burden.

• #43 Medications to Treat Mast Cell Diseases – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/treatments/medications-treat-mast-cell-diseases/

  Targeted Therapies/ Small Molecule Inhibitors may be prescribed for Selected Patients with Smoldering and Advanced Variants of Systemic Mastocytosis: Ayvakit® (Avapritinib for ASM and ISM), Gleevec® (Imatinib), Masivet® (Masitinib), Rydapt® (Midostaurin), Sprycel® (Dasatinib), Tasigna® (Nilotinib). […] Conventional Chemotherapy that may be prescribed for Selected Patients with Smoldering and Advanced Variants of Systemic Mastocytosis: Hydrea® (Hydroxyurea), Leustatin® (Cladribine, 2-CDA). […] Immunotherapy that may be prescribed for Selected Patients with Smoldering and Advanced Variants of Systemic Mastocytosis: Intron® (Interferon Alfa-2b). […] There are several more therapies in the pipeline, including additional tyrosine kinase inhibitors and other targeted therapies. […] Sometimes symptoms change, and it becomes necessary to increase or decrease doses of medications, or to add additional medications to a patient’s prescribed protocol.

• #44 Treatment of Indolent and Advanced Systemic Mastocytosis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9084172/

  Recently, a relevant role has been reported for Omalizumab to resolve cardiovascular symptoms with or without anaphylaxis. When this approach is ineffective, a cytoreductive therapy with cladribine or interferon (IFN) can be taken into consideration. […] A cytoreductive treatment is not recommended for ISM and SSM unless anti-mediator therapy has failed. […] Midostaurin is a multikinase inhibitor that is able to inhibit the kinase activity of both wild-type and D816V mutated KIT. […] Masitinib, an oral tyrosine kinase inhibitor, was used in a randomized, double-blind, placebo-controlled phase 3 trial. […] Avapritinib (BLU-285), a multikinase inhibitor, is a second-generation inhibitor of KIT D816V. […] Cladribine is a synthetic purine analog that inhibits DNA repair, blocks dividing cells, and induces apoptosis in resting cells.

• #45

  https://www.nhs.uk/conditions/mastocytosis/treatment/

  Cladribine is an alternative medicine to midostaurin. […] Avapritinib is a medicine that can be used to treat advanced systemic mastocytosis in adults. […] Systemic mastocytosis with associated blood (haematological) disease will be treated in the same way as aggressive systemic mastocytosis, with a number of additional treatments for the related haematological condition. […] Because of your increased risk of anaphylaxis, you may be given an adrenaline auto-injector to use in an emergency.

• #46 Mastocytosis and Mast Cell Activation Syndrome – Immunology; Allergic Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/immunology-allergic-disorders/allergic-autoimmune-and-other-hypersensitivity-disorders/mastocytosis-and-mast-cell-activation-syndrome

  Cromolyn may help by preventing mast cell degranulation. Ketotifen may also be effective. No treatment can reduce the number of tissue mast cells. […] Omalizumab is an anti-IgE antibody that is sometimes used for moderate to severe asthma and chronic urticaria; it has sometimes been used in patients with mastocytosis or mast cell activation syndrome to try to prevent anaphylaxis. […] In patients with an aggressive form of mastocytosis, characterized by increasing mast cell accumulation in different organs, leading to dysfunction, the multikinase inhibitors midostaurin or avapritinib can be used to help control end-organ damage, cytopenias, and mast cell accumulation in bone marrow. […] Avapritinib can also be used for symptomatic management in indolent mastocytosis. […] Interferon alfa-2b induces regression of bone lesions. Corticosteroids may be required as adjunctive treatment for severe cases. […] Treatment is directed at preventing mediator release (eg, with cromolyn and/or ketotifen) and blocking mediator effects with some regimen of H1 and H2 blockers to block histamine, aspirin to block prostaglandins and montelukast to block leukotrienes.

• #47

  https://www.nhs.uk/conditions/mastocytosis/treatment/

  More severe symptoms of cutaneous mastocytosis, such as severe itchy skin, may require a type of treatment called psoralen plus ultraviolet A (PUVA). […] If symptoms such as itchiness are particularly severe, corticosteroid tablets (oral corticosteroids) may be prescribed on a short-term basis. […] If you have weakened bones (osteoporosis) resulting from abnormal mast cell activity in your bones, you’ll be given a medicine called bisphosphonates. […] Originally designed to treat cancer, interferon alpha has proved effective in treating some cases of aggressive mastocytosis. […] Imatinib is an alternative medicine to interferon alpha. […] Nilotinib or dasatinib may be recommended if you do not respond to treatment with imatinib. […] Midostaurin is a licensed medicine that can be used to treat advanced systemic mastocytosis.

• #48 Systemic Mastocytosis Treatment & Management: Medical Care, Surgical Care, Consultations

  https://emedicine.medscape.com/article/203948-treatment

  Tyrosine kinase inhibitors (TKIs) have shown benefit in treatment of systemic mastocytosis. In 2017, the FDA approved midostaurin (Rydapt), which inhibits multiple receptor tyrosine kinases, for aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell leukemia (MCL), collectively referred to as advanced systemic mastocytosis. […] In 2021, the FDA approved avapritinib (Ayvakit) for treatment of adult patients with advanced systemic mastocytosis (AdvSM). […] The TKI imatinib mesylate (Gleevec) may be useful in those types of systemic mastocytosis that do not have mutations of the codon 816 on the c-kit gene and carry the wild-type kit. […] Allogeneic hematopoietic cell transplantation is the only treatment that has the proven ability to cure advanced systemic mastocytosis but is considered experimental and is being pursued in clinical trials at the US National Institutes of Health (NIH).

• #49 What are treatments for Systemic Mastocytosis? – HealthTree for Systemic Mastocytosis

  https://healthtree.org/mastocytosis/community/what-are-treatments-for-systemic-mastocytosis

  Steroids such as prednisone reduce inflammation and have been used to control gastrointestinal issues like malabsorption, fluid build-up in the abdomen, stomach pain, bone pain, and skin disease that doesn’t respond to topical treatment. Steroids can also be used to prevent anaphylaxis. […] Proton pump inhibitors, such as omeprazole, help with stomach pain and other gastrointestinal symptoms. […] Calcium and Vitamin D prevent bone weakness (osteoporosis) and fractures. […] Chemotherapy can reduce the number of mast cells in the body, helping to control symptoms and prevent complications. These drugs work by interfering with the growth of mast cells, thereby reducing their numbers. One chemotherapy drug commonly used is Cladribine (Leustatin). […] For patients with life-threatening systemic mastocytosis, allogeneic stem cell transplantation may be considered. This involves replacing the patient’s diseased bone marrow (which produces mast cells) with healthy bone marrow from a donor. This can potentially cure the disease, but it carries significant risks, including infection, graft-versus-host disease, and even death. Therefore, it is usually reserved for the most severe cases.

• #50 What are treatments for Systemic Mastocytosis? – HealthTree for Systemic Mastocytosis

  https://healthtree.org/mastocytosis/community/what-are-treatments-for-systemic-mastocytosis

  Steroids such as prednisone reduce inflammation and have been used to control gastrointestinal issues like malabsorption, fluid build-up in the abdomen, stomach pain, bone pain, and skin disease that doesn’t respond to topical treatment. Steroids can also be used to prevent anaphylaxis. […] Proton pump inhibitors, such as omeprazole, help with stomach pain and other gastrointestinal symptoms. […] Calcium and Vitamin D prevent bone weakness (osteoporosis) and fractures. […] Chemotherapy can reduce the number of mast cells in the body, helping to control symptoms and prevent complications. These drugs work by interfering with the growth of mast cells, thereby reducing their numbers. One chemotherapy drug commonly used is Cladribine (Leustatin). […] For patients with life-threatening systemic mastocytosis, allogeneic stem cell transplantation may be considered. This involves replacing the patient’s diseased bone marrow (which produces mast cells) with healthy bone marrow from a donor. This can potentially cure the disease, but it carries significant risks, including infection, graft-versus-host disease, and even death. Therefore, it is usually reserved for the most severe cases.

• #51 Advanced Systemic Mastocytosis: Treatment and Forms of the Condition

  https://www.healthline.com/health/advanced-systemic-mastocytosis-faqs

  Advanced systemic mastocytosis is a progressive condition characterized by the accumulation of mast cells in the bodys organs. […] Theres no cure for advanced systemic mastocytosis, but many of the symptoms can be treated. […] For people with aggressive forms of the disorder, cladribine, midostaurin, and bone marrow transplants can help slow its progression. […] There is no cure for advanced systemic mastocytosis, but many of the symptoms can be treated. […] Treatments may include: […] Cladribine, a kind of chemotherapeutic that targets immune cells, is also often used for people with advanced systemic mastocytosis. […] For some people with advanced systemic mastocytosis, midostaurin can help as well. […] A bone marrow transplant may also help slow the progression of disease.

• #52 Medications to Treat Mast Cell Diseases – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/treatments/medications-treat-mast-cell-diseases/

  Targeted Therapies/ Small Molecule Inhibitors may be prescribed for Selected Patients with Smoldering and Advanced Variants of Systemic Mastocytosis: Ayvakit® (Avapritinib for ASM and ISM), Gleevec® (Imatinib), Masivet® (Masitinib), Rydapt® (Midostaurin), Sprycel® (Dasatinib), Tasigna® (Nilotinib). […] Conventional Chemotherapy that may be prescribed for Selected Patients with Smoldering and Advanced Variants of Systemic Mastocytosis: Hydrea® (Hydroxyurea), Leustatin® (Cladribine, 2-CDA). […] Immunotherapy that may be prescribed for Selected Patients with Smoldering and Advanced Variants of Systemic Mastocytosis: Intron® (Interferon Alfa-2b). […] There are several more therapies in the pipeline, including additional tyrosine kinase inhibitors and other targeted therapies. […] Sometimes symptoms change, and it becomes necessary to increase or decrease doses of medications, or to add additional medications to a patient’s prescribed protocol.

• #53 Bezuclastinib was safe and rapidly lowered markers of disease burden for patients with nonadvanced systemic mastocytosis in Phase II trial | MD Anderson Cancer Center

  https://www.mdanderson.org/newsroom/ash–targeted-oral-therapy-reduced-disease-burden-improved-symptoms-patients-rare-blood-disorder.h00-159624168.html

  Bezuclastinib was safe and rapidly lowered markers of disease burden for patients with nonadvanced systemic mastocytosis in Phase II trial. […] The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results of the Phase II SUMMIT trial reported by researchers at The University of Texas MD Anderson Cancer Center. […] The findings, presented today at the 2023 American Society of Hematology (ASH) Annual Meeting, demonstrate that all participants treated with bezuclastinib achieved at least a 50% reduction in markers of disease burden and 63% reported their disease symptoms eased within 12 weeks. […] Bezuclastinib provides precision targeting without the typical central nervous system or bleeding side effects often associated with similar drugs.

• #54 Bezuclastinib was safe and rapidly lowered markers of disease burden for patients with nonadvanced systemic mastocytosis in Phase II trial | MD Anderson Cancer Center

  https://www.mdanderson.org/newsroom/ash–targeted-oral-therapy-reduced-disease-burden-improved-symptoms-patients-rare-blood-disorder.h00-159624168.html

  Bezuclastinib is a potent type-1 tyrosine kinase inhibitor that blocks mutant KIT D816V activity while sparing other kinases, minimizing the potential for off-target side effects. […] Patients who received the 100 mg dose experienced a median reduction in symptoms of 48.5% after 12 weeks. […] „This drug may offer great promise in the treatment of non-advanced systemic mastocytosis,” Bose said. […] To further assess the drugs efficacy in patients with NonAdvSM, next steps for the SUMMIT trial include comparing bezuclastinib against placebo once the optimal dose is known with certainty.

• #55 Treatments – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/treatments/

  Treatment of mastocytosis depends on the symptoms and the classification of disease. Symptoms of mast cell activation/mediator release are treated with H1 and H2 antihistamines, mast cell stabilizers, leukotriene inhibitors, and possibly aspirin (under direct supervision of a physician). All mast cell disease patients should carry two doses of self-injectable epinephrine, unless otherwise contraindicated (glucagon may need to be administered for patients on beta-blockers). Patients should also be instructed on how to self-administer the epinephrine while lying down, to maximize rapid absorption of the drug. Every patient should carry a physician-signed American Academy of Allergy, Asthma and Immunology Anaphylaxis Action Plan at all times. […] Treatment of MCAS is similar to that listed above for mastocytosis symptoms related to mast cell activation and mediator release.

• #56 Treatment of Indolent and Advanced Systemic Mastocytosis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9084172/

  Oral psoralen combined with ultraviolet therapy is reserved for patients with cutaneous mastocytosis (urticarial pigmentosa) in case of severe/resistant skin symptoms. […] H2-antagonists (ranitidine 150 mg bid, famotidine 10 mg bid, cimetidine 400 mg bid) are the drug of choice in case of gastrointestinal symptoms. Proton pump inhibitors (omeprazole 20 mg, pantoprazole 40 mg, rabeprazole 20 mg) are second line drugs in case H2-antihistamines are not effective. Sodium cromolyn at a dose of 8001200 mg daily divided into four doses is a third-line treatment. Oral corticosteroids (prednisone 0.51 mg/kg/day or equivalent) are the fourth-line drug for gastrointestinal symptoms. […] The prevalence of anaphylaxis in adults with SM ranges from 22 to 49%, about 100 times higher than the general population. Anaphylaxis may be provoked by a concomitant IgE-mediated allergy (especially to Hymenoptera venoms) or may also be spontaneous. Thus, all patients should be prescribed self-injectable epinephrine and should be trained to treat attacks.

• #57 Treatments – TMS – The Mast Cell Disease Society, IncAccessibilityIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://tmsforacure.org/treatments/

  Treatment of mastocytosis depends on the symptoms and the classification of disease. Symptoms of mast cell activation/mediator release are treated with H1 and H2 antihistamines, mast cell stabilizers, leukotriene inhibitors, and possibly aspirin (under direct supervision of a physician). All mast cell disease patients should carry two doses of self-injectable epinephrine, unless otherwise contraindicated (glucagon may need to be administered for patients on beta-blockers). Patients should also be instructed on how to self-administer the epinephrine while lying down, to maximize rapid absorption of the drug. Every patient should carry a physician-signed American Academy of Allergy, Asthma and Immunology Anaphylaxis Action Plan at all times. […] Treatment of MCAS is similar to that listed above for mastocytosis symptoms related to mast cell activation and mediator release.

• #58 Mastocytosis and Mast Cell Activation Syndrome – Immunology; Allergic Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/immunology-allergic-disorders/allergic-autoimmune-and-other-hypersensitivity-disorders/mastocytosis-and-mast-cell-activation-syndrome

  Mastocytosis is mast cell proliferation with infiltration of skin or other tissues and organs. Treatment is with antihistamines and control of any underlying disorder. […] For cutaneous mastocytosis, H1 blockers and possibly psoralen plus ultraviolet light or topical corticosteroids. […] For systemic mastocytosis and mast cell activation syndrome, H1 and H2 blockers, cromolyn, ketotifen, montelukast, and aspirin. […] For aggressive forms, midostaurin, avapritinib, interferon alfa-2b, or corticosteroids. […] H1 blockers are effective for symptoms. […] Management of anaphylactic reactions includes parenteral epinephrine, inhaled beta-agonists for wheezing, and IV fluid replacement for hypotension. […] All patients with systemic mastocytosis should be treated with H1 and H2 blockers and should carry a prefilled, self-injecting epinephrine syringe.

• #59 Treatment of Indolent and Advanced Systemic Mastocytosis

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9084172/

  The role of allogeneic stem cell transplantation is still not defined in the treatment of disease: debulk strategy, the timing of the procedure, choice of best conditioning regimen and donor source, and possible maintenance therapy post-transplant are still matter of debate in the clinical practice. […] Mastocytosis is a complex disease for which a multidisciplinary approach is mandatory for a comprehensive evaluation and choice of therapy. In most cases, patients might need a personalized treatment with a specific combination of different drugs, ranging from antihistamines and bisphosphonates to TKI and chemotherapy.

• #60 Mastocytosis Center – Brigham and Women’s Hospital

  https://www.brighamandwomens.org/medicine/allergy-clinical-immunology/allergy-mastocytosis-center

  The Mastocytosis Center at Brigham and Womens Hospital has been providing care for adults and children with mast cell activation disorders for over 20 years. […] Ongoing research includes basic investigations into the biology of human mast cells at the DNA, RNA and protein level, translational research in mast cell activation disorders, and clinical trials with new therapeutic options, including monoclonal antibodies and biological agents. […] The Center is a multi-specialty group and includes physicians from: Allergy and Clinical Immunology, Gastroenterology, Dermatology, Neurology, Oncology/Hematology, Endocrinology, Pulmonology and Pathology. […] We have developed treatment innovations such as the first ultra-rush venom desensitization protocol for patients with mastocytosis and life-threatening anaphylaxis to hymenoptera venom.

• #61 Current and Emergent Therapies for Systemic Mastocytosis

  https://www.targetedonc.com/view/current-and-emergent-therapies-for-systemic-mastocytosis

  The field of mastocytosis is witnessing a paradigm shift with precision medicine in the form of mutant KIT inhibitors. […] The options have been limited to trigger avoidance, supportive care using drugs such as proton pump inhibitors, H1 and H2 blockers, leukotriene antagonists and mast cell stabilizers, and use of epinephrine pens for management of anaphylaxis. […] However, the field is fortunately witnessing a paradigm shift with precision medicine in the form of mutant KIT inhibitors. […] The findings led to a major shift in treatment approach from cladribine/interferon to KIT inhibition and formed the basis of regulatory approval of the drug. […] Together, these studies led to the approval of avapritinib for patients with advanced SM. Improved outcomes and a better adverse event profile compared with midostaurin have led to avapritinib being preferred in patients with advanced SM.

• #62 Current and Emergent Therapies for Systemic Mastocytosis

  https://www.targetedonc.com/view/current-and-emergent-therapies-for-systemic-mastocytosis

  The arrival of potent C-KIT inhibitors has ushered in a new area in the management of SM. Patients with advanced SM now have a targeted therapy available that provides more frequent and deeper remissions. […] On the other hand, for those with nonadvanced SM, the approval of avapritinib is a major win that improves symptoms and quality of life and possibly modifies the underlying disease biology.

• #63 Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis | Leukemia

  https://www.nature.com/articles/s41375-022-01615-z

  In conclusion, the results from this analysis show that patients with AdvSM treated with avapritinib experienced significantly improved survival, longer DOT, as well as greater reductions in serum tryptase levels, compared to patients treated with BAT. These data offer important insights into the superior comparative efficacy of avapritinib relative to other therapies for AdvSM.

• #64 Bezuclastinib was safe and rapidly lowered markers of disease burden for patients with nonadvanced systemic mastocytosis in Phase II trial | MD Anderson Cancer Center

  https://www.mdanderson.org/newsroom/ash–targeted-oral-therapy-reduced-disease-burden-improved-symptoms-patients-rare-blood-disorder.h00-159624168.html

  Bezuclastinib is a potent type-1 tyrosine kinase inhibitor that blocks mutant KIT D816V activity while sparing other kinases, minimizing the potential for off-target side effects. […] Patients who received the 100 mg dose experienced a median reduction in symptoms of 48.5% after 12 weeks. […] „This drug may offer great promise in the treatment of non-advanced systemic mastocytosis,” Bose said. […] To further assess the drugs efficacy in patients with NonAdvSM, next steps for the SUMMIT trial include comparing bezuclastinib against placebo once the optimal dose is known with certainty.

Zobacz więcej